The SNF5 antibody targets the SNF5 protein, also known as SMARCB1 or INI1. a core subunit of the SWI/SNF chromatin-remodeling complex. This evolutionarily conserved complex regulates gene expression by altering chromatin structure to modulate DNA accessibility. SNF5 functions as a tumor suppressor, and its inactivation through mutations or deletions is strongly linked to aggressive cancers, including malignant rhabdoid tumors and epithelioid sarcomas. Antibodies against SNF5 are widely used in research to study its expression, localization, and interaction partners. They play a critical role in confirming SNF5 loss in diagnostic pathology, as its absence is a hallmark of certain malignancies. These antibodies are validated for applications like Western blotting, immunohistochemistry, and immunofluorescence, with specificity confirmed using knockout controls. Studies using SNF5 antibodies have also shed light on the broader roles of SWI/SNF complexes in development, differentiation, and cancer biology. Recent work explores synthetic lethal interactions in SNF5-deficient cancers, highlighting its therapeutic relevance. Proper validation remains essential due to potential cross-reactivity with related proteins in the SWI/SNF family.